1. Home
  2. AKBA vs FGII Comparison

AKBA vs FGII Comparison

Compare AKBA & FGII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.22

Market Cap

251.0M

Sector

Health Care

ML Signal

HOLD

FGII

FG Imperii Acquisition Corp. Class A Ordinary Shares

N/A

Current Price

$9.95

Market Cap

288.0M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
AKBA
FGII
Founded
2007
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
251.0M
288.0M
IPO Year
2014
2026

Fundamental Metrics

Financial Performance
Metric
AKBA
FGII
Price
$1.22
$9.95
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$4.67
N/A
AVG Volume (30 Days)
4.1M
30.1K
Earning Date
05-07-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
93.94
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$9.86
52 Week High
$3.81
$9.99

Technical Indicators

Market Signals
Indicator
AKBA
FGII
Relative Strength Index (RSI) 46.66 55.75
Support Level $1.16 N/A
Resistance Level $1.52 $9.96
Average True Range (ATR) 0.07 0.01
MACD -0.02 -0.00
Stochastic Oscillator 7.59 66.67

Price Performance

Historical Comparison
AKBA
FGII

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About FGII FG Imperii Acquisition Corp. Class A Ordinary Shares

FG Imperii Acquisition Corp is a blank check company incorporated in the Cayman Islands. The company was formed for the purpose of merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities.

Share on Social Networks: